Date: 2015-05-11
Type of information: Construction of new premises
Compound:
Company: Alexion Pharmaceuticals (USA - CT)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: construction of new premises
Action mechanism:
Disease:
Details: * On May 11, 2015, Alexion Pharmaceuticals announced plans to significantly expand its operations in Ireland by constructing the Company’s first ever biologics manufacturing facility outside the United States. This €450 million, four-year project will be constructed at Alexion’s College Park site in Blanchardstown. It is expected to create approximately 200 additional full-time jobs on completion, which will bring Alexion’s total workforce in Ireland to almost 500 employees. Operations in this new Irish factory will include biologics manufacturing, vial fill-finish and global supply chain.
Financial terms:
Latest news:
